Provectus Abstract Titled “Chemoablation of Melanoma with Intralesional Rose Bengal (PV-10)" to be Presented at ASCO Scientific Program on June 1 in Orlando
--Interim Phase 2 Bystander Correlation Data to Be Included in Presentation--
--Will Also Participate in a Satellite Symposium to be Held At ASCO--
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Apr 28, 2009 - Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced today that a poster, Abstract #9060, entitled “Chemoablation of melanoma with intralesional rose bengal (PV-10)," will be presented on June 1, 2009 in the 8:00 a.m. – 12:00 p.m. General Poster Session (Group F, Brd. F15), at the 2009 American Society of Clinical Oncology (ASCO) Scientific Program at the Orange County Convention Center in Orlando, Florida.
Dr. Sanjiv S. Agarwala, Principal Investigator for Provectus' Phase 2 PV-10 trial site at St. Luke's Hospital & Health Network in Bethlehem, PA will present an update on the development efforts with PV-10 for metastatic melanoma, including interim Phase 2 safety and efficacy data on the first 40 subjects in the trial and interim bystander correlation data on response of untreated tumors in subjects whose treated tumors responded successfully. Additional Phase 1 survival data will be also be presented.
Provectus will also participate in a Satellite Symposium to the 2009 ASCO Annual Meeting entitled “Developing the Next Generation of Immunotherapeutic Strategies for Solid Tumors.” The Satellite Symposium, featuring a presentation by Dr. Agarwala, will be held on May 30, 2009 at 6:30 p.m. in Orlando, Florida.
According to the American Cancer Society, in 2008 there were approximately 62,000 new cases of melanoma in the U.S., leading to more than 8,000 deaths. Further, the World Health Organization has estimated that 48,000 patients globally died from melanoma in 2008.
About Provectus Pharmaceuticals, Inc. (www.pvct.com)
Provectus Pharmaceuticals is a development stage company that specializes in oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional therapies. Provectus is currently conducting Phase 2 clinical trials of its proprietary drugs PV-10 as a therapy for metastatic melanoma and PH-10 as a topical treatment for psoriasis and atopic dermatitis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. The Company has received orphan drug designation from the FDA for its melanoma indication. Complementing their suite of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of imaging, medical devices and biotechnology. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.
Contact: Provectus Pharmaceuticals, Inc.
Peter R. Culpepper, CFO, 866-594-5999 #30
Porter, LeVay & Rose, Inc.
Marlon Nurse, VP
Bill Gordon, SVP
Posted: April 2009